[go: up one dir, main page]

ECSP10010722A - Compuestos orgánicos - Google Patents

Compuestos orgánicos

Info

Publication number
ECSP10010722A
ECSP10010722A EC2010010722A ECSP10010722A ECSP10010722A EC SP10010722 A ECSP10010722 A EC SP10010722A EC 2010010722 A EC2010010722 A EC 2010010722A EC SP10010722 A ECSP10010722 A EC SP10010722A EC SP10010722 A ECSP10010722 A EC SP10010722A
Authority
EC
Ecuador
Prior art keywords
organic compounds
formula
methods
pharmaceutical compositions
present
Prior art date
Application number
EC2010010722A
Other languages
English (en)
Inventor
Julien Papillon
Qi-Ying Hu
Leslie Wighton Mcquire
Christopher Adams
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010722A publication Critical patent/ECSP10010722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos orgánicos novedosos de la fórmula I; métodos de uso, y composiciones farmacéuticas de los mismos.
EC2010010722A 2008-06-27 2010-12-27 Compuestos orgánicos ECSP10010722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7645208P 2008-06-27 2008-06-27

Publications (1)

Publication Number Publication Date
ECSP10010722A true ECSP10010722A (es) 2011-01-31

Family

ID=41445020

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010722A ECSP10010722A (es) 2008-06-27 2010-12-27 Compuestos orgánicos

Country Status (25)

Country Link
US (4) US8791141B2 (es)
EP (1) EP2307371B1 (es)
JP (2) JP5542809B2 (es)
KR (1) KR101264525B1 (es)
CN (2) CN102076665B (es)
AR (1) AR072297A1 (es)
AU (1) AU2009264220B9 (es)
BR (1) BRPI0914698A2 (es)
CA (1) CA2729108A1 (es)
CO (1) CO6321282A2 (es)
CR (1) CR11861A (es)
EA (1) EA018731B1 (es)
EC (1) ECSP10010722A (es)
ES (1) ES2654044T3 (es)
HN (1) HN2010002772A (es)
IL (1) IL209726A0 (es)
MA (1) MA32509B1 (es)
MX (1) MX2010014356A (es)
MY (1) MY153915A (es)
NZ (1) NZ589666A (es)
PE (1) PE20100055A1 (es)
TW (1) TW201004936A (es)
UY (1) UY31940A (es)
WO (1) WO2009156462A2 (es)
ZA (1) ZA201008535B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
MX2011010482A (es) * 2009-04-06 2012-01-30 Ptc Therapeutics Inc Compustos y métodos para tratamiento antiviral.
US20120022078A1 (en) * 2009-04-09 2012-01-26 Msd K.K. Aryl indole derivatives
EA201101621A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
CN102803217B (zh) * 2009-05-15 2015-06-17 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基吡啶
BRPI1012203A2 (pt) 2009-05-15 2016-04-05 Novartis Ag derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
JP5654608B2 (ja) * 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
PT2523731T (pt) 2010-01-14 2019-01-21 Novartis Ag Uso de um agente modificador de hormona adrenal
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
JP5584238B2 (ja) * 2011-01-25 2014-09-03 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩の医薬用途
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
CA2886117C (en) * 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9522141B2 (en) 2012-12-20 2016-12-20 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CN104530000B (zh) * 2014-12-12 2016-07-20 重庆博腾制药科技股份有限公司 一种醛固酮合酶调节剂中间体的制备方法
EP3240778A4 (en) * 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物
KR102729280B1 (ko) * 2016-10-28 2024-11-12 서울대학교병원 3-아미노알킬레이티드 인돌 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018125800A2 (en) * 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
CN107382783B (zh) * 2017-07-17 2019-06-18 中国科学院化学研究所 一种手性β-氨基酸衍生物及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
KR102220428B1 (ko) * 2018-08-08 2021-02-25 한국과학기술연구원 Ship2 저해활성을 보이는 신규한 피리딘 유도체 및 이를 유효성분으로 하는 약학 조성물
CN109411788B (zh) * 2018-09-28 2021-07-13 北京化工大学 氮杂螺环阳离子负载型聚联苯碱性膜及其制备方法
WO2020102616A1 (en) * 2018-11-16 2020-05-22 Nimbus Artemis, Inc. Acly inhibitors and uses thereof
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
WO2020146532A1 (en) 2019-01-08 2020-07-16 Sparks Steven Metalloenzyme inhibitor compounds
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V A portion of an antibody against FAP
CN112745270B (zh) * 2020-12-30 2023-02-24 河北医科大学 新化合物及其制备苯唑草酮中间体的方法
CN113943257B (zh) * 2021-09-06 2024-06-14 青岛科技大学 一种光催化c-3位烷基取代喹喔啉-2(1h)-酮类化合物的合成方法及应用
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
CN115286790B (zh) * 2022-07-12 2023-05-23 太原理工大学 一种碘捕获材料及其制备方法和应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409626A (en) 1963-09-17 1968-11-05 Neisler Lab Inc Indolylethyl pyridinium quaternary ammonium compounds
US3370063A (en) 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3381006A (en) 1964-10-05 1968-04-30 Mcneilab Inc Certain beta-substituted-alpha-(4, 5-dimethoxy-2-nitrophenyl) acrylonitriles and 2-aminophenyl derivatives thereof
US3467670A (en) 1964-10-05 1969-09-16 Mcneilab Inc 2-phenyl-3-amido-5,6-dimethoxyindoles
US3501310A (en) 1966-03-11 1970-03-17 Eastman Kodak Co Direct positive silver halide emulsions containing compounds which accept electrons and spectrally sensitize the emulsion
US3505070A (en) 1966-03-11 1970-04-07 Eastman Kodak Co Direct positive emulsion containing dimethine dyes containing a 2-aromatically substituted indole nucleus
US3468894A (en) * 1966-11-29 1969-09-23 Geigy Chem Corp Certain 2-pyridyl-substituted indole derivatives
US3501484A (en) 1968-01-15 1970-03-17 Miles Lab Certain substituted 3 - (2-indolyl)-1,2,5,6-tetrahydropyridines and derivatives thereof
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
SU703527A1 (ru) 1978-01-03 1979-12-15 Донецкий государственный университет Способ получени 1-формилкарбазола
US4226868A (en) 1978-09-25 1980-10-07 Eastman Kodak Company Processes for inhibiting the growth of sea urchin eggs
US4232121A (en) 1978-09-25 1980-11-04 Eastman Kodak Company Process for selecting methine dyes which inhibit cell growth
JPS55151505A (en) 1979-05-14 1980-11-26 Kuraray Co Ltd Indole agricultural and horticultural fungicide
US4355098A (en) 1981-02-11 1982-10-19 E. I. Du Pont De Nemours And Company Supersensitizing direct positive dye combinations
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
GB2111050B (en) * 1981-11-19 1985-09-11 Ciba Geigy Ag N-substituted-2-pyridylindoles
US4460777A (en) 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4950680A (en) 1983-03-31 1990-08-21 Board Of Governors Of Wayne State University Method and compositions for inhibition of tumor cell induced platelet aggregation
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
JPS61282834A (ja) 1985-06-08 1986-12-13 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
DE3530825A1 (de) 1985-08-29 1987-03-05 Boehringer Mannheim Gmbh Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3621761A1 (de) 1986-06-28 1988-01-07 Bayer Ag Indolylpropionsaeuren
GB8626297D0 (en) 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8626296D0 (en) 1986-11-04 1986-12-03 Ici Plc Therapeutic agents
US4839271A (en) 1987-06-26 1989-06-13 E. I. Du Pont De Nemours And Company Direct positive dimethine cyanine dyes containing 1-aryl-2-heteroaryl indole nucleus
EP0300675A3 (en) 1987-07-21 1990-04-11 Merck Frosst Canada Inc. Method for the improvement of cyclosporine therapy
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
DE3740985A1 (de) 1987-12-03 1989-06-15 Boehringer Mannheim Gmbh Verwendung linear anellierter tricyclen als hemmer der erythrozytenaggregation
JPH0285251A (ja) 1988-09-22 1990-03-26 Nissan Chem Ind Ltd 植物生長調節剤
US5166170A (en) 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5021448A (en) 1990-02-22 1991-06-04 Ciba-Geigy Corporation Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
CA2075057A1 (en) 1990-03-15 1991-09-16 Pharmacia & Upjohn Company Llc Therapeutically useful heterocyclic indole compounds
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
FR2679561A1 (fr) 1991-07-26 1993-01-29 Schneider Marc Nouveaux derives de l'(indolyl-1) alkylamine substituee par une chaine presentant des groupements carbonyles conjugues a un noyau aromatique.
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
WO1993019067A1 (en) 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine derivatives as angiotensin ii antagonists
JPH07507271A (ja) 1992-03-03 1995-08-10 藤沢薬品工業株式会社 アンジオテンシン１１拮抗剤としてのベンズイミダゾール誘導体
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5952355A (en) 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
EP0680950B1 (en) 1993-11-17 2001-05-23 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
JP3155008B2 (ja) 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE69705324T2 (de) 1996-12-26 2001-10-11 Nikken Chemicals Co., Ltd. N-hydroxyharnstoffderivate und sie enthaltende medizinische zubereitungen
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
ATE296805T1 (de) 1997-06-19 2005-06-15 Bristol Myers Squibb Pharma Co Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
ES2198033T3 (es) 1997-12-19 2004-01-16 Eli Lilly And Company Compuestos de imidazolina hipoglucemicos.
DE69828998T2 (de) 1997-12-24 2006-05-04 Nikem Research S.R.L., Baranzate Di Bollate Indolderivate verwendbar zur behandlung von u.a. osteoporosis
TR200002446T2 (tr) 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz enzimlerinin inhibitörleri
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
JP2002513018A (ja) 1998-04-29 2002-05-08 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン作動薬
DK1076558T3 (da) * 1998-05-15 2003-11-03 Wyeth Corp 2-Phenyl-1-[4-(2-aminoethoxy)benzyl]indol i kombination med østrogener
DE69942801D1 (de) * 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6436997B1 (en) 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
JPH11344787A (ja) 1998-06-03 1999-12-14 Konica Corp ハロゲン化銀カラー写真感光材料
AU5648599A (en) 1998-09-11 2000-04-03 Kyorin Pharmaceutical Co. Ltd. Phosphonic ester derivatives and process for producing the same
AU779117B2 (en) 1998-12-18 2005-01-06 Axys Pharmaceuticals, Inc. Protease inhibitors
WO2000039102A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
WO2000044743A1 (en) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Amide derivatives and drug compositions
US6380185B1 (en) * 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
AU1887401A (en) 1999-12-14 2001-06-25 Nippon Shinyaku Co. Ltd. Medicinal composition
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2001089519A1 (en) 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
WO2002000646A1 (en) 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
KR20030059084A (ko) 2000-07-31 2003-07-07 스미스크라인 비참 피.엘.시. 카르복사미드 화합물 및 이것의 사람 11ｃｂｙ 수용체의길항제로서의 용도
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2004522369A (ja) 2001-07-04 2004-07-22 エルジー エレクトロニクス インコーポレイティド 家庭用機器を用いたサービスシステム及びこれを用いたサービス方法
AU2002336311B8 (en) 2001-10-25 2009-04-23 Asahi Kasei Pharma Corporation Bicyclic compound
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
JP2003342276A (ja) 2002-05-24 2003-12-03 Mitsui Chemicals Inc ピロロキナゾリン誘導体及び農園芸用有害生物防除剤ならびにその使用方法
PT1539742E (pt) 2002-06-24 2007-01-31 Schering Corp Derivados de índole úteis como antagonistas h3 de histamina
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
WO2004048331A1 (en) * 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
BRPI0315958B8 (pt) * 2002-11-28 2021-05-25 Suven Life Sciences Ltd composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
WO2004069394A2 (en) 2003-02-03 2004-08-19 The Trustees Of Columbia University In The City Of New York Synthetic method for direct arylation of heterocyclic arenes
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
WO2004100998A2 (en) 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20060205751A1 (en) * 2003-07-15 2006-09-14 Smithkline Beecham Corporation Novel compounds
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
CN101031539A (zh) 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途
JP4794446B2 (ja) 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリン系カリウムチャンネル阻害薬
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
UA86962C2 (en) 2004-02-20 2009-06-10 Бёрингер Ингельхайм Интернациональ Гмбх Viral polymerase inhibitors
US20050277639A1 (en) 2004-03-02 2005-12-15 Phil Skolnick 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
AU2005227289B2 (en) 2004-03-08 2012-03-08 Boehringer Ingelheim Pharmaceuticals, Inc. Process for cross coupling indoles
WO2005090302A2 (en) 2004-03-16 2005-09-29 Boehringer Ingelheim International Gmbh Palladium catalyzed indolization of 2-bromo or chloroanilines
US20050245517A1 (en) 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102004034380A1 (de) 2004-07-16 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verwendung von TRIAL und IkappaB-Kinase Inhibitoren in der Krebsbehandlung
US20080275028A1 (en) 2004-07-20 2008-11-06 Giovanni Gaviraghi Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
EP1807424B1 (en) 2004-10-29 2012-04-18 Abbott Laboratories Novel kinase inhibitors
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
EP1863756A1 (en) 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
JP2006290791A (ja) 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
CN101137655A (zh) 2005-06-17 2008-03-05 配体药物公司 雄激素受体调节剂化合物和方法
AU2006261931A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
JP2009512732A (ja) 2005-10-24 2009-03-26 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤および照射の組合せ
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007061763A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
KR20080079250A (ko) 2005-12-06 2008-08-29 뉴로서치 에이/에스 신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도
JP2009526776A (ja) 2006-02-14 2009-07-23 ノイロサーチ アクティーゼルスカブ 新規なジアザビシクロアルカン誘導体及びその医療上の使用
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
US20090312311A1 (en) 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
SI2007756T1 (sl) 2006-04-07 2015-11-30 Vertex Pharmaceuticals Incorporated Modulatorji prenašalcev z atp-vezavno kaseto
GB0610322D0 (en) 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
CA2672286A1 (en) 2006-12-18 2008-06-26 Novartis Ag Organic compounds
CA2672940A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
JP2010520275A (ja) 2007-03-06 2010-06-10 アストラゼネカ・アクチエボラーグ 新規な２−ヘテロアリール置換インドール６９５
EP2150112A1 (en) 2007-04-26 2010-02-10 Merck & Co., Inc. 2-substituted indole derivatives as calcium channel blockers
EP2018861A1 (en) 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
WO2009062319A1 (en) 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
EP2262497A2 (en) 2008-03-17 2010-12-22 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.

Also Published As

Publication number Publication date
EA018731B1 (ru) 2013-10-30
BRPI0914698A2 (pt) 2015-10-20
MY153915A (en) 2015-04-15
ZA201008535B (en) 2012-01-25
CN104193725B (zh) 2016-11-16
WO2009156462A3 (en) 2010-05-27
JP5542809B2 (ja) 2014-07-09
US20100261698A1 (en) 2010-10-14
US20110082129A1 (en) 2011-04-07
PE20100055A1 (es) 2010-02-25
JP2014139252A (ja) 2014-07-31
NZ589666A (en) 2012-06-29
CN102076665A (zh) 2011-05-25
US20150210672A1 (en) 2015-07-30
MX2010014356A (es) 2011-02-21
JP2011525894A (ja) 2011-09-29
WO2009156462A2 (en) 2009-12-30
TW201004936A (en) 2010-02-01
CA2729108A1 (en) 2009-12-30
KR101264525B1 (ko) 2013-05-14
ES2654044T3 (es) 2018-02-12
CN102076665B (zh) 2014-09-03
US8030334B2 (en) 2011-10-04
US20140288126A1 (en) 2014-09-25
CO6321282A2 (es) 2011-09-20
EA201100037A1 (ru) 2011-08-30
AU2009264220B2 (en) 2012-08-23
HN2010002772A (es) 2013-04-22
EP2307371B1 (en) 2017-10-04
EP2307371A2 (en) 2011-04-13
JP5753927B2 (ja) 2015-07-22
IL209726A0 (en) 2011-02-28
US8791141B2 (en) 2014-07-29
US9242963B2 (en) 2016-01-26
KR20110025223A (ko) 2011-03-09
AU2009264220B9 (en) 2012-10-04
CN104193725A (zh) 2014-12-10
UY31940A (es) 2010-01-29
CR11861A (es) 2011-02-16
MA32509B1 (fr) 2011-07-03
AR072297A1 (es) 2010-08-18
AU2009264220A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
ECSP10010722A (es) Compuestos orgánicos
EA201170772A1 (ru) Органические соединения
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
DOP2011000176A (es) Compuestos organicos
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
CR20140135A (es) Nuevos derivados de aril-quinolina
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
PA8792401A1 (es) Fenilendiaminas
UA106880C2 (uk) Нові гербіциди
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY31688A1 (es) Plaguicidas